FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2981379812> ?p ?o ?g. }

• W2981379812 endingPage "S1038" @default.
• W2981379812 startingPage "S1037" @default.
• W2981379812 abstract "Therapy surveillance is a corner stone in advanced lung cancer clinical management. Due to the ease of sampling, analysis of tumor derived circulating DNA in plasma for treatment monitoring and decision making is desirable. Patients with tumors harboring a sensitizing EGFR mutation benefit from targeted therapy using tyrosine kinase inhibitors (TKIs). Unfortunately, the majority of patients develop resistance towards the initially administered TKI either through intrinsic mechanisms of EGFR or mutations of additional genes such as amplification of MET. Osimertinib can be administered at disease progression due to the resistance mutation T790M in EGFR. In this study we used liquid biopsy at progression after TKI treatment to assess mutational status of sensitizing and T790M mutations. In some cases, a tumor biopsy was analyzed in parallel as part of clinical management. Six 10 ml Streck Cell free BCT® tubes were collected and plasma was isolated. Cell free circulating DNA was purified and used in an ultra-sensitive ddPCR assay IBSAFE (George et al, manuscript in preparation). Both the sensitizing EGFR mutation and T790M was analyzed. In some cases, a solid biopsy was analyzed in the clinic in parallel to our plasma analysis. Patient outcome data will be collected from patient files. Eighteen of 25 patients tested positive in plasma for the previously known sensitizing EGFR mutation (72%). Twelve of 25 tested positive in plasma for T790M mutation (48%). Among plasma samples positive for the sensitizing mutation, 67% were also positive for T790M. The minor allele frequency (MAF) fraction of T790M in comparison to the sensitizing mutation varied extensively from 0.01% to 90% and also the MAF compared to total DNA varied (0.005% to 23%). Updated clinical follow up data will be presented. For a subset of patients were a tumor biopsy is not feasible, a liquid biopsy could provide information about the mutational status. As the MAF vary considerably and can be very low, a highly sensitive assay such as the IBSAFE ddPCR assay, capable of confirming a mutation at a MAF as low as 0.005% is advantageous. Further, a large plasma input volume may aid in identifying patients positive for mutations at a low MAF. Updated clinical follow up data will be discussed." @default.
• W2981379812 created "2019-11-01" @default.
• W2981379812 creator A5002955183 @default.
• W2981379812 creator A5016805282 @default.
• W2981379812 creator A5017989225 @default.
• W2981379812 creator A5048584813 @default.
• W2981379812 creator A5051144449 @default.
• W2981379812 creator A5056172056 @default.
• W2981379812 creator A5058677345 @default.
• W2981379812 creator A5082180772 @default.
• W2981379812 creator A5090170824 @default.
• W2981379812 date "2019-10-01" @default.
• W2981379812 modified "2023-09-30" @default.
• W2981379812 title "EP1.14-16 Use of Digital Droplet PCR for Detecting EGFR T790M Resistance Mutation in Plasma at Progression on TKI Therapy" @default.
• W2981379812 doi "https://doi.org/10.1016/j.jtho.2019.08.2301" @default.
• W2981379812 hasPublicationYear "2019" @default.
• W2981379812 type Work @default.
• W2981379812 sameAs 2981379812 @default.
• W2981379812 citedByCount "0" @default.
• W2981379812 crossrefType "journal-article" @default.
• W2981379812 hasAuthorship W2981379812A5002955183 @default.
• W2981379812 hasAuthorship W2981379812A5016805282 @default.
• W2981379812 hasAuthorship W2981379812A5017989225 @default.
• W2981379812 hasAuthorship W2981379812A5048584813 @default.
• W2981379812 hasAuthorship W2981379812A5051144449 @default.
• W2981379812 hasAuthorship W2981379812A5056172056 @default.
• W2981379812 hasAuthorship W2981379812A5058677345 @default.
• W2981379812 hasAuthorship W2981379812A5082180772 @default.
• W2981379812 hasAuthorship W2981379812A5090170824 @default.
• W2981379812 hasBestOaLocation W29813798121 @default.
• W2981379812 hasConcept C104317684 @default.
• W2981379812 hasConcept C121608353 @default.
• W2981379812 hasConcept C126322002 @default.
• W2981379812 hasConcept C143998085 @default.
• W2981379812 hasConcept C152110520 @default.
• W2981379812 hasConcept C156719811 @default.
• W2981379812 hasConcept C172680121 @default.
• W2981379812 hasConcept C182707283 @default.
• W2981379812 hasConcept C2776256026 @default.
• W2981379812 hasConcept C2777626846 @default.
• W2981379812 hasConcept C2777930144 @default.
• W2981379812 hasConcept C2778087573 @default.
• W2981379812 hasConcept C2778258057 @default.
• W2981379812 hasConcept C2779234561 @default.
• W2981379812 hasConcept C2779438470 @default.
• W2981379812 hasConcept C2779529041 @default.
• W2981379812 hasConcept C2780580887 @default.
• W2981379812 hasConcept C48126324 @default.
• W2981379812 hasConcept C49105822 @default.
• W2981379812 hasConcept C501734568 @default.
• W2981379812 hasConcept C502942594 @default.
• W2981379812 hasConcept C54355233 @default.
• W2981379812 hasConcept C71924100 @default.
• W2981379812 hasConcept C86803240 @default.
• W2981379812 hasConceptScore W2981379812C104317684 @default.
• W2981379812 hasConceptScore W2981379812C121608353 @default.
• W2981379812 hasConceptScore W2981379812C126322002 @default.
• W2981379812 hasConceptScore W2981379812C143998085 @default.
• W2981379812 hasConceptScore W2981379812C152110520 @default.
• W2981379812 hasConceptScore W2981379812C156719811 @default.
• W2981379812 hasConceptScore W2981379812C172680121 @default.
• W2981379812 hasConceptScore W2981379812C182707283 @default.
• W2981379812 hasConceptScore W2981379812C2776256026 @default.
• W2981379812 hasConceptScore W2981379812C2777626846 @default.
• W2981379812 hasConceptScore W2981379812C2777930144 @default.
• W2981379812 hasConceptScore W2981379812C2778087573 @default.
• W2981379812 hasConceptScore W2981379812C2778258057 @default.
• W2981379812 hasConceptScore W2981379812C2779234561 @default.
• W2981379812 hasConceptScore W2981379812C2779438470 @default.
• W2981379812 hasConceptScore W2981379812C2779529041 @default.
• W2981379812 hasConceptScore W2981379812C2780580887 @default.
• W2981379812 hasConceptScore W2981379812C48126324 @default.
• W2981379812 hasConceptScore W2981379812C49105822 @default.
• W2981379812 hasConceptScore W2981379812C501734568 @default.
• W2981379812 hasConceptScore W2981379812C502942594 @default.
• W2981379812 hasConceptScore W2981379812C54355233 @default.
• W2981379812 hasConceptScore W2981379812C71924100 @default.
• W2981379812 hasConceptScore W2981379812C86803240 @default.
• W2981379812 hasIssue "10" @default.
• W2981379812 hasLocation W29813798121 @default.
• W2981379812 hasOpenAccess W2981379812 @default.
• W2981379812 hasPrimaryLocation W29813798121 @default.
• W2981379812 hasRelatedWork W2767471949 @default.
• W2981379812 hasRelatedWork W2767888602 @default.
• W2981379812 hasRelatedWork W2777429645 @default.
• W2981379812 hasRelatedWork W2887887720 @default.
• W2981379812 hasRelatedWork W2889982944 @default.
• W2981379812 hasRelatedWork W2943857365 @default.
• W2981379812 hasRelatedWork W2961956354 @default.
• W2981379812 hasRelatedWork W2968141797 @default.
• W2981379812 hasRelatedWork W3013327955 @default.
• W2981379812 hasRelatedWork W3149588583 @default.
• W2981379812 hasVolume "14" @default.
• W2981379812 isParatext "false" @default.
• W2981379812 isRetracted "false" @default.
• W2981379812 magId "2981379812" @default.
• W2981379812 workType "article" @default.